Ocugen Statistics
Total Valuation
Ocugen has a market cap or net worth of $427.21 million. The enterprise value is $407.66 million.
| Market Cap | 427.21M |
| Enterprise Value | 407.66M |
Important Dates
The next estimated earnings date is Monday, August 19, 2024, after market close.
| Earnings Date | Aug 19, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Ocugen has 257.35 million shares outstanding. The number of shares has increased by 14.06% in one year.
| Shares Outstanding | 257.35M |
| Shares Change (YoY) | +14.06% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 12.85% |
| Float | 253.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 15.22 |
| PS Ratio | 60.60 |
| Forward PS | n/a |
| PB Ratio | 14.12 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 57.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.87, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.87 |
| Quick Ratio | n/a |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -117.30% and return on invested capital (ROIC) is -161.74%.
| Return on Equity (ROE) | -117.30% |
| Return on Assets (ROA) | -83.60% |
| Return on Capital (ROIC) | -161.74% |
| Revenue Per Employee | $108,462 |
| Profits Per Employee | -$900,062 |
| Employee Count | 65 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +176.44% in the last 52 weeks. The beta is 3.75, so Ocugen's price volatility has been higher than the market average.
| Beta (5Y) | 3.75 |
| 52-Week Price Change | +176.44% |
| 50-Day Moving Average | 1.66 |
| 200-Day Moving Average | 0.99 |
| Relative Strength Index (RSI) | 49.40 |
| Average Volume (20 Days) | 7,822,472 |
Short Selling Information
The latest short interest is 53.12 million, so 20.64% of the outstanding shares have been sold short.
| Short Interest | 53.12M |
| Short Previous Month | 49.06M |
| Short % of Shares Out | 20.64% |
| Short % of Float | 20.97% |
| Short Ratio (days to cover) | 7.91 |
Income Statement
In the last 12 months, Ocugen had revenue of $7.05 million and -$58.50 million in losses. Loss per share was -$0.25.
| Revenue | 7.05M |
| Gross Profit | 7.05M |
| Operating Income | -60.00M |
| Pretax Income | -58.50M |
| Net Income | -58.50M |
| EBITDA | -57.25M |
| EBIT | -58.50M |
| Loss Per Share | -$0.25 |
Balance Sheet
The company has $26.38 million in cash and $6.83 million in debt, giving a net cash position of $19.54 million or $0.08 per share.
| Cash & Cash Equivalents | 26.38M |
| Total Debt | 6.83M |
| Net Cash | 19.54M |
| Net Cash Per Share | $0.08 |
| Equity (Book Value) | 30.26M |
| Book Value Per Share | 0.12 |
| Working Capital | 13.95M |
Cash Flow
In the last 12 months, operating cash flow was -$54.41 million and capital expenditures -$11.22 million, giving a free cash flow of -$65.63 million.
| Operating Cash Flow | -54.41M |
| Capital Expenditures | -11.22M |
| Free Cash Flow | -65.63M |
| FCF Per Share | -$0.26 |
Margins
Gross margin is 100.00%, with operating and profit margins of -851.01% and -829.84%.
| Gross Margin | 100.00% |
| Operating Margin | -851.01% |
| Pretax Margin | -829.84% |
| Profit Margin | -829.84% |
| EBITDA Margin | -812.03% |
| EBIT Margin | -829.84% |
| FCF Margin | -930.85% |
Dividends & Yields
Ocugen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.06% |
| Shareholder Yield | -14.06% |
| Earnings Yield | -13.69% |
| FCF Yield | -15.36% |
Analyst Forecast
The average price target for Ocugen is $4.67, which is 181.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.67 |
| Price Target Difference | 181.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 87.51% |
| EPS Growth Forecast (5Y) | -39.89% |
Stock Splits
The last stock split was on September 30, 2019. It was a reverse split with a ratio of 1:60.
| Last Split Date | Sep 30, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:60 |
Scores
Ocugen has an Altman Z-Score of 0.58 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.58 |
| Piotroski F-Score | 2 |